专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO02057303A3 PROTEIN-PROTEIN INTERACTIONS BETWEEN SHIGELLA FLEXNERI POLYPEPTIDES AND MAMMALIAN POLYPEPTIDES 审中-公开
标题翻译：蛋白质与蛋白质之间的相互作用
公开(公告)号：WO02057303A3
公开(公告)日：2003-12-24
申请号：PCT/EP0200777
申请日：2002-01-11
申请人： HYBRIGENICS SA , LEGRAIN PIERRE
发明人： LEGRAIN PIERRE
IPC分类号： A61K38/00 , A61K39/00 , C07K14/25 , C12N15/31 , C12Q1/02 , G01N33/50 , C12N15/11 , C12Q1/68 , G01N33/68
CPC分类号： G01N33/5014 , A61K38/00 , A61K39/00 , A61K2039/523 , C07K14/25 , C12Q1/025 , G01N33/5008 , G01N33/502 , G01N2333/25
摘要： The present invention relates to protein-protein interactions between Shigella polypeptides and mammalian polypeptides. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies, to the complexes, Selected Interacting Domains (SID3) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical composition that are capable of modulating the protein-protein interactions.
摘要翻译：本发明涉及志贺氏菌多肽和哺乳动物多肽之间的蛋白质 - 蛋白质相互作用。更具体地，本发明涉及编码多肽的复合物，多肽的片段，抗体的复合物，由于蛋白质 - 蛋白质相互作用而鉴定的选择性相互作用域（SID3），筛选药物的方法调节蛋白质和能够调节蛋白质 - 蛋白质相互作用的药物组合物的相互作用的试剂。

2. 发明申请

WO02060934A3 IDENTIFICATION OF THE ANTI- sigma <28> FACTOR IN HELICOBACTER PYLORI, IN CAMPYLOBACTER JEJUNI AND IN PSEUDOMONAS AERUGINOSA AND APPLICATION THEREOF 审中-公开
标题翻译：鉴定抗生素黄酮，琼脂糖凝胶中和抗氧化酶AERUGINOSA中的抗性28因子及其应用
公开(公告)号：WO02060934A3
公开(公告)日：2003-03-20
申请号：PCT/EP0201625
申请日：2002-01-28
申请人： HYBRIGENICS SA , PASTEUR INSTITUT , LEGRAIN PIERRE , COLLAND FREDERIC , RAIN JEAN-CHRISTOPHE , LABIGNE AGNES , DE REUSE HILDE
发明人： LEGRAIN PIERRE , COLLAND FREDERIC , RAIN JEAN-CHRISTOPHE , LABIGNE AGNES , DE REUSE HILDE
IPC分类号： C07K14/205 , C07K14/21 , C12N1/21 , C12N15/31 , C12N15/63
CPC分类号： C07K14/21 , C07K14/205
摘要： The present invention relates to the function of a polypeptides named HP1122, Cj1464 and PA3351 which are the anti- sigma factor of Helicobacter pylori, Campylobacter jejuni and Pseudomonas aeruginosa, respectively. The present invention also relates to a polypeptide named SID1122 which is the domain of Helicobacter pylori's HP1122 polypeptide involved in a specific interaction with Helicobacter pylori sigma (HP1032) and which has an anti- sigma factor activity. More specifically, the present invention relates to SID1122 polypeptide that interact with HP1032, identification of the HP1032 interacting domain (SID1032) that is specifically involved in the interaction with HP1122, complexes of two polypeptides such as HP1122 HP1032, or SID1122 SID1032, fragments and variants of the SID1122 and SID1032 polypeptides, antibodies to the SID1122 and SID1032 polypeptides, methods for screening drugs or agents which modulate the interaction of Helicobacter pylori's polypeptides encoded by HP1122 and HP1032 and pharmaceutical compositions for treating or preventing Gram negative flagellated bacteria infection in a human or mammal, more specifically Helicobacter sp. or Campylobacter jejuni or Pseudomonas aeruginosa infection, in particular Helicobacter pylori infection in a human or a mammal.
摘要翻译：本发明涉及分别作为幽门螺杆菌抗幽门螺杆菌，空肠弯曲杆菌和铜绿假单胞菌的抗HP1122，Cj1464和PA3351的多肽的功能。本发明还涉及一种称为SID1122的多肽，其是幽门螺杆菌HP1122多肽的参与与幽门螺杆菌σ28（HP1032）的特异性相互作用并且具有抗西格玛28因子活性的结构域。更具体地，本发明涉及与HP1032相互作用的SID1122多肽，特异性参与与HP1122的相互作用的HP1032相互作用结构域（SID1032）的鉴定，两种多肽如HP1122 HP1032或SID1122 SID1032的复合物，片段和变体 SID1122和SID1032多肽的抗体，SID1122和SID1032多肽的抗体，用于筛选调节由HP1122和HP1032编码的幽门螺杆菌多肽的相互作用的药物或药剂的方法和用于治疗或预防人类革兰氏阴性鞭毛细菌感染的药物组合物，哺乳动物，更具体地说是幽门螺杆菌或空肠弯曲杆菌或铜绿假单胞菌感染，特别是人或哺乳动物的幽门螺杆菌感染。

3. 发明申请

WO02053726A3 PROTEIN-PROTEIN INTERACTIONS IN ADIPOCYTE CELLS 审中-公开
标题翻译：蛋白质 - 蛋白质相互作用在ADIPOCYTE细胞
公开(公告)号：WO02053726A3
公开(公告)日：2003-03-13
申请号：PCT/EP0115423
申请日：2001-12-28
申请人： HYBRIGENICS SA , CENTRE NAT RECH SCIENT , LEGRAIN PIERRE , MARULLO STEFANO , JOCKERS RALF
发明人： LEGRAIN PIERRE , MARULLO STEFANO , JOCKERS RALF
IPC分类号： C07K14/47 , C07K14/705 , C12N15/12 , C12N15/10 , A61K45/00 , C07K14/435
CPC分类号： C07K14/47 , C07K14/705
摘要： The present invention relates to protein-protein interactions of adipocyte. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes. Selected Interacting Domains (SID3) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.
摘要翻译：本发明涉及脂肪细胞的蛋白质 - 蛋白质相互作用。更具体地，本发明涉及编码多肽的多肽或多核苷酸的复合物，多肽的片段，复合物的抗体。由于蛋白质 - 蛋白质相互作用而鉴定出的选定的相互作用域（SID3），用于筛选调节蛋白质和能够调节蛋白质 - 蛋白质相互作用的药物组合物相互作用的试剂的药物的方法。

4. 发明申请

WO0250261A3 PROTEINS THAT INTERACT WITH beta TRCP 审中-公开
标题翻译：与βTRCP相互作用的蛋白质
公开(公告)号：WO0250261A3
公开(公告)日：2002-12-19
申请号：PCT/EP0115414
申请日：2001-12-18
申请人： HYBRIGENICS SA , INST NAT SANTE RECH MED , LEGRAIN PIERRE , BENAROUS RICHARD , BLOT GUILLAUME , LASSOT IRINA
发明人： LEGRAIN PIERRE , BENAROUS RICHARD , BLOT GUILLAUME , LASSOT IRINA
IPC分类号： A61K38/00 , C07K14/47 , A61K48/00 , C07K16/18 , C12N9/00 , C12N15/10
CPC分类号： C07K14/47 , A61K38/00
摘要： The present invention relates to proteins that interaction with beta TrCP. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID3*) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.
摘要翻译：本发明涉及与β-TrCP相互作用的蛋白质。更具体地，本发明涉及编码多肽的多肽或多核苷酸的复合物，多肽的片段，复合物的抗体，由于蛋白质 - 蛋白质相互作用而鉴定的选择性相互作用域（SID3 *），筛选药物的方法调节蛋白质和能够调节蛋白质 - 蛋白质相互作用的药物组合物的相互作用的试剂。

5. 发明申请

WO0066722B1 COLLECTION OF PROKARYOTIC DNA FOR TWO HYBRID SYSTEMS HELICOBACTER PYLORI PROTEIN-PROTEIN INTERACTIONS AND APPLICATION THEREOF 审中-公开
标题翻译：用于两个混合系统的真核DNA的收集HELICOBACTER PYLORI蛋白质 - 蛋白质相互作用及其应用
公开(公告)号：WO0066722B1
公开(公告)日：2001-02-01
申请号：PCT/IB0000603
申请日：2000-04-14
申请人： HYBRIGENICS SA , LEGRAIN PIERRE , SELIG LUC , RAIN JEAN CHRISTOPHE
发明人： LEGRAIN PIERRE , SELIG LUC , RAIN JEAN-CHRISTOPHE
IPC分类号： G01N33/50 , A61K35/76 , A61K38/00 , A61K39/106 , A61K39/395 , A61K39/40 , A61K45/00 , A61K48/00 , C07K14/195 , C07K14/205 , C07K14/245 , C07K14/315 , C07K16/12 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/10 , C12N15/31 , C12N15/86 , C12P21/02 , C12P21/08 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566 , G06F17/00
CPC分类号： C12N15/1055 , C07K14/205
摘要： The present invention concerns collections of recombinant cell clones derived from a prokaryotic genome, more particularly from Helicobacter pylori genome, usable for two-hybrid systems and methods to produce such collections. The invention further relates to the identification of H. pylori protein-protein interactions and to the application of said collections of recombinant cell clones and said identified proteins interactions to the pharmaceutical and diagnostic field.
摘要翻译：本发明涉及来源于原核基因组，特别是来自幽门螺杆菌基因组的重组细胞克隆的集合，可用于双杂交系统和产生这种收集物的方法。本发明还涉及幽门螺杆菌蛋白质 - 蛋白质相互作用的鉴定以及所述重组细胞克隆集合的应用和所述鉴定的蛋白质相互作用在药物和诊断领域中的应用。

6. 发明申请

WO2020120644A1 NEW ANTI TAU SVQIVYKPV EPITOPE SINGLE DOMAIN ANTIBODY 审中-公开
公开(公告)号：WO2020120644A1
公开(公告)日：2020-06-18
申请号：PCT/EP2019/084774
申请日：2019-12-12
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE LILLE , CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , HYBRIGENICS SA
发明人： BUEE, Luc , LANDRIEU, Isabelle , RAIN, Jean-Christophe , DUPRE, Elian , ARRIAL, Alexis , DANIS, Clément
IPC分类号： C07K16/18 , G01N33/68 , A61P25/28
摘要： The invention relates to generation, optimization and characterisation of VHH targeted against Tau MTBD (microtubule-binding domain) with high affinity, obtained by screening from a naïve synthetic library. The inventors optimized version of a lead VHH which is able to inhibit Tau aggregation in vitro and in HEK 293 aggregation-reporting cellular model, providing a new tool in Tau immunotherapies. Accordingly the invention relates to new VHH antibody that specifically binds with high affinity Tau species, especially the epitope region involved in Tau aggregation. Moreover, the inventors found that immunization with the optimized version of this lead VHH prevented the formation of neurofibrillary tangles induced by injection of extracellular h-AD in mouse model. Thus, these specific antibodies can be used for the therapy of tauopathy disorders such as Progressive supranuclear palsy (PSP).

7. 发明申请

WO2013030218A4 SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 审中-公开
标题翻译：选择性和可逆的泛素特异性蛋白酶抑制剂7
公开(公告)号：WO2013030218A4
公开(公告)日：2013-04-25
申请号：PCT/EP2012066741
申请日：2012-08-29
申请人： HYBRIGENICS SA , COLLAND FREDERIC , GOURDEL MARIE-EDITH
发明人： COLLAND FREDERIC , GOURDEL MARIE-EDITH
IPC分类号： C07D401/06 , A61K31/517 , A61P3/00 , A61P9/00 , A61P19/00 , A61P25/00 , A61P31/00 , A61P35/00 , A61P37/00 , C07D409/14
CPC分类号： C07D401/06 , A61K31/517 , A61K45/06 , C07D239/88 , C07D239/91 , C07D409/14
摘要： The present invention relates to quinazolin-4-one compounds of formula (I'), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly USP7, for treating e.g. cancer, neurodegenerative diseases, inflammatory disorders and viral infections.
摘要翻译：本发明涉及式（I'）的喹唑啉-4-酮化合物，其制备方法和用途。这些化合物可用作泛素特异性蛋白酶，特别是USP7的选择性和可逆性抑制剂，用于治疗例如，癌症，神经退行性疾病，炎性病症和病毒感染。

8. 发明申请

WO2010145903A1 NEW THERAPEUTICAL USES OF INECALCITOL 审中-公开
标题翻译：新西兰内科治疗新疗法
公开(公告)号：WO2010145903A1
公开(公告)日：2010-12-23
申请号：PCT/EP2010/056832
申请日：2010-05-18
申请人： HYBRIGENICS SA , DELANSORNE, Rémi , DUFOUR-LAMARTINIE, Jean-François
发明人： DELANSORNE, Rémi , DUFOUR-LAMARTINIE, Jean-François
IPC分类号： A61K31/593 , A61P3/02 , A61P19/10 , A61P17/06 , A61P3/08 , A61P13/08 , A61P35/00 , A61P5/18
CPC分类号： A61K31/593
摘要： The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D relevant disease comprising administering inecalcitol at doses comprised between 1 mg/day and 100 mg/day to a human patient in need thereof.
摘要翻译：因此，本发明涉及治疗和/或预防r ets病，骨质疏松症，骨软化症，牛皮癣，自身免疫疾病如多发性硬化或I型糖尿病，甲状旁腺功能亢进，良性前列腺增生，任何类型的癌症或任何维生素D相关疾病的方法，其包括施用对于需要其的人类患者，其剂量为1mg /天至100mg /天。

9. 发明申请

WO2007017758A3 NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS 审中-公开
公开(公告)号：WO2007017758A3
公开(公告)日：2007-02-15
申请号：PCT/IB2006/002637
申请日：2006-07-26
申请人： HYBRIGENICS SA , GUEDAT, Philippe , BOISSY, Guillaume , BORG-CAPRA, Catherine , COLLAND, Frédéric , DAVIET, Laurent , FORMSTECHER, Etienne , JACQ, Xavier , RAIN, Jean-Christophe , DELANSORNE, Rémi , VALLESE, Stefania , COLOMBO, Matteo
发明人： GUEDAT, Philippe , BOISSY, Guillaume , BORG-CAPRA, Catherine , COLLAND, Frédéric , DAVIET, Laurent , FORMSTECHER, Etienne , JACQ, Xavier , RAIN, Jean-Christophe , DELANSORNE, Rémi , VALLESE, Stefania , COLOMBO, Matteo
IPC分类号： C07D241/38 , A61K31/495 , A61P35/00 , A61P25/28 , A61P9/00 , A61P31/00
摘要： The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.

10. 发明申请

WO2003098521A3 METHOD FOR ORGANIZING AND QUERYING GENOMIC AND PROTEOMIC DATABASES 审中-公开
公开(公告)号：WO2003098521A3
公开(公告)日：2003-11-27
申请号：PCT/IB2003/001801
申请日：2003-04-09
申请人： HYBRIGENICS SA , DURAND, Patrick , WOJCIK, Jérome , SCHACHTER, Vincent
发明人： DURAND, Patrick , WOJCIK, Jérome , SCHACHTER, Vincent
IPC分类号： G06F19/00
摘要： The method organizes genomic and proteomic information in a organized database having a plurality of data nodes and a plurality of links capable to bind data nodes two by two, genomic and proteomic information being stored in a plurality of independent databases The access method to access by query to the contents of a database organized by the preceding organization method comprises, for a defined query, steps of: a) organizing of the query in the form of a graph pattern comprising a plurality of nodes and a plurality of links binding the nodes two by two, the nodes and the links being taken in the set of data node types and links types respectively of the organized database b) seeking in the database of a set of nodes and links whose type corresponding to the said query thus organized, the said set of nodes and links forming a set of occurrences of the graph pattern; c) provisioning the terminal with the said set of nodes and links.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式